In BRAFV600E+ melanoma cells, an aberrant activation of this intracellular pathway has been reported to mediate resistance to BRAF and MEK inhibitors and to support the acquisition of stem-like properties [205,206]. This evidence concerns the gene MAP2K7 and melanoma.